Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity
- PMID: 19915059
- DOI: 10.4049/jimmunol.0902697
Endogenous IL-21 restricts CD8+ T cell expansion and is not required for tumor immunity
Abstract
IL-21 has antitumor activity through actions on NK cells and CD8(+) T cells, and is currently in clinical development for the treatment of cancer. However, no studies have addressed the role of endogenous IL-21 in tumor immunity. In this study, we have studied both primary and secondary immune responses in IL-21(-/-) and IL-21R(-/-) mice against several experimental tumors. We found intact immune surveillance toward methylcholanthrene-induced sarcomas in IL-21(-/-) and IL-21R(-/-) mice compared with wild-type mice and B16 melanomas showed equal growth kinetics and development of lung metastases. IL-21R(-/-) mice showed competent NK cell-mediated rejection of NKG2D ligand (Rae1beta) expressing H-2b(-) RMAS lymphomas and sustained transition to CD8(+) T cell-dependent memory against H-2b(+) RMA lymphomas. alpha-Galactosylceramide stimulation showed equal expansion and activation of NKT and NK cells and mounted a powerful antitumor response in the absence of IL-21 signaling, despite reduced expression of granzyme B in NKT, NK, and CD8(+) T cells. Surprisingly, host IL-21 significantly restricted the expansion of Ag-specific CD8(+) T cells and inhibited primary CD8(+) T cell immunity against OVA-expressing EG7 lymphomas, as well as the secondary expansion of memory CD8(+) T cells. However, host IL-21 did not alter the growth of less immunogenic MC38 colon carcinomas with dim OVA expression. Overall, our results show that endogenous IL-21/IL-21R is not required for NK, NKT, and CD8(+) T cell-mediated tumor immunity, but restricts Ag-specific CD8(+) T cell expansion and rejection of immunogenic tumors, indicating novel immunosuppressive actions of this cytokine.
Similar articles
-
CD1d-restricted NKT cell activation enhanced homeostatic proliferation of CD8+ T cells in a manner dependent on IL-4.Int Immunol. 2006 Sep;18(9):1397-404. doi: 10.1093/intimm/dxl073. Epub 2006 Aug 16. Int Immunol. 2006. PMID: 16914507
-
Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells.Cancer Res. 2000 Nov 15;60(22):6457-64. Cancer Res. 2000. PMID: 11103813
-
Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.J Immunol. 1998 Dec 15;161(12):6977-84. J Immunol. 1998. PMID: 9862733
-
[Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].Strahlenther Onkol. 2004 Apr;180(4):187-93. doi: 10.1007/s00066-004-9119-x. Strahlenther Onkol. 2004. PMID: 15057428 Review. German.
-
IL-21: roles in immunopathology and cancer therapy.Tissue Antigens. 2009 Dec;74(6):467-79. doi: 10.1111/j.1399-0039.2009.01382.x. Epub 2009 Oct 21. Tissue Antigens. 2009. PMID: 19845910 Review.
Cited by
-
Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression.J Immunol. 2012 Apr 1;188(7):3127-37. doi: 10.4049/jimmunol.1103433. Epub 2012 Feb 17. J Immunol. 2012. PMID: 22345665 Free PMC article.
-
Endogenous IL-21 regulates pathogenic mucosal CD4 T-cell responses during enhanced RSV disease in mice.Mucosal Immunol. 2013 Jul;6(4):704-17. doi: 10.1038/mi.2012.108. Epub 2012 Nov 21. Mucosal Immunol. 2013. PMID: 23168836 Free PMC article.
-
Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells.PLoS One. 2012;7(1):e30264. doi: 10.1371/journal.pone.0030264. Epub 2012 Jan 18. PLoS One. 2012. PMID: 22279576 Free PMC article.
-
Reprogramming the tumor microenvironment by genome editing for precision cancer therapy.Mol Cancer. 2022 Apr 11;21(1):98. doi: 10.1186/s12943-022-01561-5. Mol Cancer. 2022. PMID: 35410257 Free PMC article. Review.
-
Cytokines and the inception of CD8 T cell responses.Trends Immunol. 2011 Apr;32(4):180-6. doi: 10.1016/j.it.2011.01.004. Epub 2011 Mar 2. Trends Immunol. 2011. PMID: 21371940 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Research Materials